ATNM - Actinium Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.2078
-0.0049 (-2.30%)
At close: 4:00PM EDT

0.2078 0.00 (0.00%)
Pre-Market: 5:05AM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.2127
Open0.2190
Bid0.2067 x 1000
Ask0.2128 x 3100
Day's Range0.2055 - 0.2190
52 Week Range0.1570 - 0.4100
Volume3,509,718
Avg. Volume5,022,888
Market Cap63.035M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-0.1470
Earnings DateJun 29, 2020 - Jun 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
    PR Newswire

    Actinium Pharmaceuticals, Inc. Announces Closing of $31.6 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the closing of the Company's previously announced underwritten public offering of 210,833,334 shares of common stock (or common stock equivalents in lieu thereof) at an effective public offering price of $0.15 per share of common stock (or common stock equivalent), which includes the full exercise of the underwriters' option to purchase additional shares of common stock.

  • Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering
    PR Newswire

    Actinium Pharmaceuticals, Inc. Announces Pricing of $27.5 Million Public Offering

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced the pricing of the Company's previously announced underwritten public offering of 183,333,334 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.15 per share of common stock (or common stock equivalent).

  • Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering
    PR Newswire

    Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or "the Company") today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in an underwritten public offering. The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of the securities to be sold in the offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020
    PR Newswire

    Actinium Provides Update on Iomab-B SIERRA Trial and Expected Topline Results from Ad Hoc Analysis in 2020

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today provided an update on the Iomab-B pivotal SIERRA (Study of Iomab-B in Elderly Relapse or Refractory Acute Myeloid Leukemia) trial incorporating the impact of the coronavirus disease (COVID-19) pandemic.

  • Can Actinium Pharmaceuticals (NYSEMKT:ATNM) Afford To Invest In Growth?
    Simply Wall St.

    Can Actinium Pharmaceuticals (NYSEMKT:ATNM) Afford To Invest In Growth?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Actinium Treats First Patient in AML Study on Actimab-A Combo
    Zacks

    Actinium Treats First Patient in AML Study on Actimab-A Combo

    Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.

  • Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia
    PR Newswire

    Actinium Pharmaceuticals Announces First Patient Treated in Third and Final Dose Cohort of Actimab-A CLAG-M Combination Phase 1 Trial in Acute Myeloid Leukemia

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that the first patient has begun treatment in the third and final cohort of the Actimab-A CLAG-M combination trial. This Phase 1 trial is an investigator-initiated trial being conducted at the Medical College of Wisconsin in patients with relapsed or refractory acute myeloid leukemia (AML). Patients in the third cohort will receive a cycle of CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) followed by 0.75 uCi/kg of Actimab-A on day 6, 7 or 8. Actimab-A is an antibody radiation conjugate (ARC) that targets the CD33 receptor on blood cancer cells and delivers potent cytotoxic radiation via the radioisotope Actinium-225. This trial will enroll up to 18 patients and will evaluate the safety of this combination including determining the maximum-tolerated dose as well as response rates, progression-free survival and overall survival. Actinium expects the third cohort to be completed mid-2020.

  • Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients
    PR Newswire

    Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it is expanding its CD33 program studying Actimab-A into a combination trial with the chemotherapy regimen 7+3 in patients with newly diagnosed acute myeloid leukemia (AML) who have intermediate or high-risk cytogenetic or molecular markers. The intent of this Phase 1 dose escalation study is to determine whether these patients can benefit from a combination of the 7+3 standard of care chemotherapy regimen, which causes DNA damage and has radiation sensitizing properties via inhibition of DNA replication and repair, with an ARC or Antibody Radiation Conjugate such as Actimab-A that delivers targeted, highly potent alpha particle radiation directly to tumor cells. This study builds upon results of an ongoing study with a similar rationale wherein a sub-therapeutic dose of Actimab-A when added to a chemotherapy regimen called CLAG-M was shown to improve responses by nearly sixty percent compared to CLAG-M given alone in relapsed or refractory AML patients. The planned Phase 1 study, if successful, could make Actimab-A a potential treatment for patients newly diagnosed with AML, which is a larger patient population than patients with refractory AML. The new trial could also support the rationale of combining ARCs with other treatment mechanisms to produce superior clinical results. To that end, Actimab-A is also being studied in a Phase 1 combination with the Bcl-2 inhibitor in patients with relapsed or refractory AML.

  • Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
    Zacks

    Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?

    Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.

  • Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
    PR Newswire

    Actinium Presents Positive Findings from Mid-Point Analysis of Pivotal SIERRA Trial of Iomab-B at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today findings from the SIERRA trial that were presented at the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT) in Orlando, FL. Dr. Boglarka Gyurkocza, the principal investigator from Memorial Sloan Kettering Cancer Center, revealed that there were key differences in side effects reported in patients treated in the Iomab-B and control arms of the study with rates of febrile neutropenia, sepsis and mucositis being markedly lower in the Iomab-B arm.

  • Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation
    PR Newswire

    Actinium to Highlight Targeted Conditioning Portfolio at 2020 Transplantation & Cellular Therapy Annual Meeting; Phase 3 SIERRA Trial Preliminary Results Selected for Oral Presentation

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that presentations from its targeted conditioning portfolio have been accepted for presentation at the 2020 Transplantation & Cellular Therapy (TCT) Meetings™, which brings together thousands of transplant professionals from over 500 transplant centers worldwide. TCT is being held February 19-23, 2020 at the Marriott World Center in Orlando, Florida. Notably, data from the pivotal Phase 3 SIERRA trial of Iomab-B have been selected for an oral presentation.

  • Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know
    Zacks

    Actinium Pharmaceuticals (ATNM) Gains But Lags Market: What You Should Know

    Actinium Pharmaceuticals (ATNM) closed at $0.24 in the latest trading session, marking a +1.04% move from the prior day.

  • Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
    PR Newswire

    Actinium Pharmaceuticals, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that Sandesh Seth, Actinium's Chairman & CEO, will be presenting at the 22nd Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Innovation Organization (BIO), the 22nd Annual BIO CEO & Investor Conference will take place February 10th and 11th at the New York Marriott Marquis in New York City.

  • Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know
    Zacks

    Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know

    Actinium Pharmaceuticals (ATNM) closed the most recent trading day at $0.26, moving -0.54% from the previous trading session.

  • Actinium (ATNM) Upgraded to Strong Buy: Here's Why
    Zacks

    Actinium (ATNM) Upgraded to Strong Buy: Here's Why

    Actinium (ATNM) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price
    Simply Wall St.

    One Thing To Remember About The Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Share Price

    Anyone researching Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) might want to consider the historical volatility of...

  • Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma
    PR Newswire

    Actinium Pharmaceuticals Announces Iomab-ACT Program Gene Therapy Collaboration with UC Davis in Ongoing Clinical Trial for Patients with HIV-Related Lymphoma

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium"), announced today that it has entered into an agreement with the University of California, Davis (UC Davis) to utilize Actinium's Antibody Radiation-Conjugate or ARC apamistamab-I-131 for targeted conditioning and replace the chemotherapy conditioning being used in an ongoing Phase 1/2 stem cell gene therapy clinical trial. In the trial, patients with relapsed or refractory HIV-related lymphoma are being treated with autologous stem cell gene therapy. This is the first gene therapy clinical trial that will utilize ARC based conditioning. The clinical trial will be conducted at UC Davis and may be expanded to additional sites in the future.

  • Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™
    PR Newswire

    Actinium Pharmaceuticals, Inc. to Present at 2020 Biotech Showcase™

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that Sandesh Seth, Actinium's Chairman and CEO, will present at the 2020 Biotech Showcase™ being held on January 13-15. The conference will be at the Hilton San Francisco Union Square. Details of Actinium's presentation are as follows:

  • Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?

    Is (ATNM) Outperforming Other Medical Stocks This Year?

  • Tilray (TLRY) in Focus: Stock Moves 9% Higher
    Zacks

    Tilray (TLRY) in Focus: Stock Moves 9% Higher

    Tilray (TLRY) shares rose 9% in the last trading session, amid huge volumes.

  • Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc (ATNM)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Actinium Pharmaceuticals Inc (ATNM)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). […]

  • Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH  2019 Annual Meeting
    PR Newswire

    Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in combination with the salvage chemotherapy regimen CLAG-M that was presented in a poster presentation at the 61st American Society of Hematology (ASH) Annual Meeting. The poster reported results from the ongoing Phase 1 combination trial that is being conducted at the Medical College of Wisconsin (MCW). Patients receiving Actimab-A at a dose of 0.50 uCi/kg in the second dose cohort in addition to CLAG-M had an 86% overall response rate (ORR), which is a 56% higher response rate and is substantially greater than what has been observed with CLAG-M and MEC and more than double that of CLAG in a similar patient population that was treated at MCW. Notably, 71% of patients (5/7) achieved negative minimal residual disease (MRD) status in the second dose cohort. In addition to response rates, the poster reported that three patients on the study proceeded to a bone marrow transplant after receiving Actimab-A and CLAG-M. The addition of Actimab-A to CLAG-M appears to have a clinically acceptable safety profile with no patient deaths reported. A table below compares the ORR of patients receiving Actimab-A and CLAG-M to that of the CLAG-M, MEC and CLAG salvage regimens. The full poster can be accessed HERE.

  • Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy
    PR Newswire

    Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

    Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") presented new findings from its pivotal Phase 3 SIERRA trial for Iomab-B (Iodine-131 apamistamab) at the 2019 American Society of Hematology (ASH) annual meeting on Sunday, December 8, 2019 in a poster presentation. Actinium is advancing the development of low dose Iodine-131 apamistamab, a CD45 targeting antibody radiation-conjugate (ARC), as an alternative to today's standard practice of chemotherapy-based lymphodepletion regimens like fludarabine/cyclophosphamide (Flu/Cy), which have been implicated in CAR-T toxicities including cytokine release syndrome (CRS) and neurotoxicity.

  • Benzinga

    The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

    Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts. Aurinia Pharmaceuticals Inc (NASDAQ: ...

  • Benzinga

    The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

    Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction ...